GlassScriptPhysician profile
William C Collis
NPI 1437151131
$1,794.18
in general payments reported to CMS, 2019-2025
17 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $123 · 2021: $127 · 2022: $280 · 2023: $484 · 2024: $351 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $786.58 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.14 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $139.18 | 2023-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $137.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.73 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $78.88 | 2023 | Assure Wcd |
| Pfizer INC. | $78.31 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $63.71 | 2022-2025 | |
| Amgen INC. | $48.15 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $46.46 | 2023-2024 | Brilinta |
| Merck Sharp & Dohme LLC | $34.60 | 2021-2022 | |
| Boston Scientific Corporation | $25.57 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $24.44 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $24.35 | 2024 | Arcalyst |
| Novo Nordisk INC | $20.62 | 2024 | Wegovy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $20.12 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Collis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.